Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct;14(10):486.
doi: 10.1007/s11910-014-0486-0.

X-linked adrenoleukodystrophy: pathogenesis and treatment

Affiliations
Review

X-linked adrenoleukodystrophy: pathogenesis and treatment

Marc Engelen et al. Curr Neurol Neurosci Rep. 2014 Oct.

Abstract

X-linked adrenoleukodystrophy (X-ALD) is a puzzling inborn error of metabolism with a strikingly heterogeneous clinical spectrum. All patients have mutations in the ABCD1 gene and accumulate very long chain fatty acids in all tissues. Virtually all male X-ALD patients develop adrenocortical insufficiency in childhood and progressive myelopathy and peripheral neuropathy in adulthood. A subset of male patients, however, develops a fatal cerebral demyelinating disease, cerebral adrenoleukodystrophy. Female patients also develop progressive myelopathy and peripheral neuropathy, but generally at a later age than males. They only very rarely develop adrenocortical insufficiency or cerebral adrenoleukodystrophy. This review proposes to simplify the classification of the clinical spectrum of X-ALD and reviews the largely unresolved pathophysiological mechanisms and the current treatment options.

PubMed Disclaimer

References

    1. Clin Chem. 2004 Oct;50(10):1824-6 - PubMed
    1. J Neurol Sci. 2010 Mar 15;290(1-2):70-4 - PubMed
    1. Br Med J. 1960 Feb 6;1(5170):402 - PubMed
    1. Neurology. 2014 May 13;82(19):1678-83 - PubMed
    1. J Neurol Neurosurg Psychiatry. 1963 Oct;26:431-8 - PubMed

MeSH terms

Substances

LinkOut - more resources